When should liothyronine be added to a patient already on a stable levothyroxine regimen?

When to Add Liothyronine to Levothyroxine Therapy

Liothyronine should be considered as a trial therapy only in patients with confirmed overt hypothyroidism who remain symptomatic despite optimized levothyroxine monotherapy (TSH 0.3-2.0 mIU/L for 3-6 months), after excluding other comorbidities, and particularly in those requiring ≥1.2 μg/kg/day of levothyroxine. 1, 2

Prerequisites Before Considering Liothyronine Addition

Confirm True Overt Hypothyroidism

• Patients with persistent symptoms but no clear biochemical evidence of overt hypothyroidism should first undergo a trial OFF thyroid hormone replacement entirely. 1 This critical step prevents unnecessary treatment of patients who may not have true hypothyroidism.

Optimize Levothyroxine First

• Target TSH should be 0.3-2.0 mIU/L and maintained for 3-6 months before assessing therapeutic response. 1
• In select cases, TSH of 0.1-0.3 mIU/L (below reference range but not fully suppressed) may be acceptable long-term. 1
• When TSH remains in the upper half of the reference range and patients continue reporting hypothyroid symptoms, increase levothyroxine to bring TSH into the lower portion of the reference range. 3

Exclude Other Causes

• Rule out malabsorption, drug interactions, poor compliance, and other comorbidities that could explain persistent symptoms. 4
• Inadequate response to levothyroxine doses >300 mcg/day is rare and suggests these alternative explanations. 4

Patient Selection Criteria for Liothyronine Trial

The ideal candidate for combination therapy has: 1, 2

• Confirmed overt hypothyroidism (not subclinical)
• Persistent dissatisfaction with levothyroxine monotherapy despite optimized dosing
• Levothyroxine requirement ≥1.2 μg/kg/day 2
• Normal TSH maintained for 3-6 months 1
• Exclusion of other medical conditions explaining symptoms

Dosing Strategy for Combination Therapy

Start by reducing levothyroxine by 25 mcg/day and adding 2.5-7.5 mcg liothyronine once or twice daily. 5

• Twice-daily dosing or slow-release formulations are preferred over single daily dosing to avoid T3 peaks. 2
• The typical ratio results in approximately 11 mcg T3 daily when TSH is normalized, though some patients require higher doses. 5
• Transient hypertriiodothyroninemia with these doses is unlikely to exceed the reference range and has not been associated with adverse reactions. 5

Safety Considerations

Combination therapy appears safe when properly regulated and monitored: 6

• Meta-analysis of RCTs (n=2,128) showed similar adverse event risk for combination versus monotherapy (RR 1.22,95% CI 0.66-2.25). 6
• Cohort studies (n=630,254) demonstrated no increased risk of atrial fibrillation (RR 1.10), heart failure (RR 1.54), or strokes (RR 0.86). 6
• Reduced mortality risk was observed with liothyronine use (RR 0.70,95% CI 0.62-0.78). 6
• Long-term observational data (mean 9 years, 400 patients) showed no increased cardiovascular disease, atrial fibrillation, or fracture risk after age adjustment. 5

Important Caveats

Shared decision-making is essential - the decision to start liothyronine must be made jointly between patient and clinician. 1 However, clinicians should not feel obligated to start or continue liothyronine if they judge it not in the patient's best interest. 1

Evidence limitations: Despite widespread use, 14 clinical trials have not shown consistent benefit of combination therapy over levothyroxine monotherapy. 2 The recommendation for trial therapy is based on patient preference data and subset analyses suggesting benefit in specific populations (particularly those with deiodinase polymorphisms). 7, 2

Avoid in subclinical hypothyroidism: Treatment of subclinical hypothyroidism (TSH <10 mIU/L) with any thyroid hormone does not improve symptoms or cognitive function in double-blinded trials. 7 Overzealous treatment of these patients contributes significantly to patient dissatisfaction. 7

Monitor appropriately: Combination therapy can restore euthyroidism while maintaining normal TSH, similar to levothyroxine monotherapy. 5 Use patient-reported outcomes as the primary measure of success. 2